Abstract: Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

Abstract: An object of the present invention is to provide a method for producing a gelatin formed body having a minimized content of a component harmful to a living body and high biocompatibility with high shaping accuracy, and a gelatin formed body produced by the method. According to the present invention, provided is a method for producing a gelatin formed body, the method including: a step a of forming, on a substrate, a layer containing a powder which is obtained by air-drying an aqueous gelatin solution and has an average particle diameter of 25 to 200 ?m; and a step b of jetting liquid droplets of an aqueous solution containing alcohols having a boiling point of 120° C. or lower toward the layer formed in the step a from a nozzle and flying the jetted liquid droplets so that the liquid droplets are landed on the layer formed in the step a, thereby forming a gelatin formed body.

Abstract: Shown here is a process for preparing a concentrated liquid composition (such as a broth) from poultry or other meat sources without the use of any enzymes. The resultant composition may have high content of solids but are pumpable or pourable and have relatively long shelf life at room temperature. Also shown are methods of extracting proteins from raw poultry or other meat sources at relatively low temperatures. Methods of making a high protein curd is also shown.

Abstract: A system and method for a chromium recovery process for recovering chromium from byproducts resulting from a tannery process. A system and process for solubilizing chromium contained in the oil byproduct into the remaining water content within the oil and extracting the water from the oil with the chromium sufficiently solubilized in the water such that the chromium content in the oil is sufficiently reduced below hazardous levels.

Abstract: A system and method for a chromium recovery process for recovering chromium from byproducts resulting from a tannery process. A system and process for solubilizing chromium contained in the oil byproduct into the remaining water content within the oil and extracting the water from the oil with the chromium sufficiently solubilized in the water such that the chromium content in the oil is sufficiently reduced below hazardous levels.

Abstract: A method for obtaining silk extract containing lutein according to an embodiment of the invention is described. The lutein extraction method uses a three solvent system for extracting bioactive lutein from silk fibers. The extracted lutein has more than 95% purity in all-E isomer with biological activity being 5 times more effective on lipid peroxidation in retina cells and twice immune stimulation in mice when compared with commercially available lutein.

Abstract: Process for producing instantaneous cold soluble gelatin in form of agglomerates of gelatin granules carried out in a fluid bed under controlled temperature, which comprises soaking the gelatin granules through atomizing a granulating liquid in the fluid bed, where the granulating liquid is made up of water.

Abstract: The present invention relates to a method for isolating proteins from a solution containing the proteins. The invention also relates to a method for the chromatographic separation of proteins. The present invention also relates to crosslinked hydroxylic polymer particles functionalized with temperature-responsive copolymer, and to methods of preparing such particles.

Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.

Abstract: The invention discloses a process for the acceleration of gelling time of regenerated silk fibroin using gelling agent, preferably silica to create a porous structure, devoid of microbial growth.

Abstract: A continuous process for the preparation of gelatin based nanoparticles in a reactor having a process channel having a mixing element therein, the process having the following steps: A) feeding separately an aqueous gelatin solution at a first rate and a water-miscible organic solvent at a second rate to the process channel of the reactor to be mixed therein, to form a suspension of non-crosslinked gelatin based nanoparticles and B) crosslinking the non-crosslinked gelatin based nanoparticles, wherein the sum of the first rate and the second rate is chosen such that the reactor has a mixing efficiency as determined by the Villermaux/Dushman method of between 0.1 and 1.5 and the period from the time point at which the aqueous gelatin solution is fed to the reactor to the time point at which the mixture of the aqueous gelatin solution and the organic solvent contacts the mixing element is at most 15 seconds.

Abstract: It is an object of the present invention to provide a protein having high cellular adhesiveness that is useful as a cell adhesion support. The present invention provides a cell-adhesive protein comprising methionine, wherein at least a portion of the methionine residues is oxidized.

Abstract: The present invention relates to methods of producing silk dope comprising silk proteins with a coiled-coil structure such as honeybee silk proteins. The silk proteins are obtained from cells producing them, solubilizing the proteins by contacting them with a surfactant or an ionic liquid and concentrating the proteins to produce silk dope. The proteins can be used for a variety of purposes such as in the production of personal care products, plastics, textiles and biomedical products.

Abstract: The invention encompasses phage ?mru including phage induction, phage particles, and the phage genome. Also encompassed are phage polypeptides, as well as polynucleotides which encode these polypeptides, expression vectors comprising these polynucleotides, and host cells comprising these vectors. The invention further encompasses compositions and methods for detecting, targeting, permeabilising, and inhibiting microbial cells, especially methanogen cells, using the disclosed phage, polypeptides, polynucleotides, expression vectors, or host cells.

Abstract: The present invention relates to modified immunoglobulin-binding proteins, e.g., Staphylococcus protein A, having improved binding specificity for immunoglobulins and methods of making and using the same.

Abstract: Signal peptides and polypeptides from Methanobrevibacter ruminantium, a methanogenic archaea present in ruminants. Methods of using these peptides to permeabilise microbial cells, particularly M. ruminantium strain M1? (DSM 1093).

Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a subject.

Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.

Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.

Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.

Abstract: A cross linked recombinant gelatin composition for the induction of blood coagulation and hemostasis.

Abstract: Labeled annexin is formed by reacting annexin or a modified annexin with a phosphatidylserine group or an analogue of phosphatidylserine. This phosphatidylserine annexin conjugate is then reacted with an appropriate label to form a labeled annexin and the annexin is separated from the phosphatidylserine group. The reaction between the phosphatidylserine group and the annexin is calcium ion concentration dependent. Therefore, the reaction can be promoted by having a high calcium ion concentration and the separation of the phosphatidyl group from the annexin group is facilitated by reducing the calcium ion concentration preferably by addition of an appropriate calcium chelating agent.

Abstract: Process for producing instantaneous cold soluble gelatin in form of agglomerates of gelatin granules carried out in a fluid bed under controlled temperature, which comprises soaking the gelatin granules through atomising a granulating liquid in the fluid bed, where the granulating liquid is made up of water.

Abstract: The invention discloses a process for the acceleration of gelling time of regenerated silk fibroin using gelling agent, preferably silica to create a porous structure, devoid of microbial growth.

Abstract: A method of producing gelatin particles, including immersing a discharge spout in a hydrophobic solvent, discharging an aqueous gelatin solution from a nozzle tip into the hydrophobic solvent, and lifting, after discharging, the nozzle from the hydrophobic solvent, which can produce particles having an object particle size in a high yield, and can produce gelatin particles that do not essentially require a classification operation.

Abstract: In joint reconstruction, repair and cushioning applications, a synthetic polypeptide material is useful that contains cross-linked polypeptides that are modeled on human elastin or other fibrous proteins. The polypeptides comprise at least three consecutive beta-sheet/beta-turn structures and at least one amino acid residue that participates in cross-linking.

Abstract: A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a crosslinking reaction to form a 3-dimensional matrix of the biomaterial.

Abstract: The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasmodium falciparum, at the erythrocyte stage, a process for purifying said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained therefrom. SE36 can be produced in Escherichia coli on a large scale by deleting all or part of polymerized serines of the 47 kd serine-repeat region, whereby high purification is permitted. The human IgG3 antibodies specifically binding to SE36 prevents highly effectively growth of the protozoa in the red blood cells to inhibit fever and cerebral malaria, and further prevent the death.

Abstract: A method of manufacturing gelatin with reduced endotoxin content. The method comprises processing a starting material gelatin-containing solution containing gelatin and an endotoxin with an ultrafiltration film having a molecular weight cut-off falling within a range of from 20,000 to 300,000 and having a molecular weight cut-off capable of passing at least a portion of the gelatin contained in the starting material gelatin-containing solution to obtain a permeate that is a gelatin-containing solution with a reduced endotoxin content. A gelatin having an average molecular weight falling within a range of 1,000 to 300,000 and an endotoxin content of less than 1 EU/mL per 1.0 percent of protein.

Abstract: A process and system for recovering protein and lipid from food animal byproducts, and the products thereof, involves homogenizing animal byproducts with water to form a homogenate, solubilizing the homogenate by adjusting the pH of the homogenate to form a first pH adjusted composition, separating the first pH adjusted composition forming a light fraction containing lipids (oil), a medium fraction containing protein in solution, and a heavy fraction containing fat-free impurities, separation by first centrifugation, adjusting the pH of the medium fraction to about the isoelectric point of the proteins thereby precipitating the medium fraction forming a second pH adjusted composition, and separating the second pH adjusted composition forming a light fraction containing water and a heavy fraction containing precipitated proteins. The water may then be recycled and used in the homogenization of further byproducts.

Abstract: The present invention provides methods for purifying insoluble bone gelatin and uses for insoluble bone gelatin. The process for isolating insoluble bone gelatin from bone tissue includes grinding the bone tissue into bone powder; washing the bone powder with saline; demineralizing the bone tissue; contacting the bone powder with a neutral salt; and contacting the bone powder with a stabilizer. The present invention also discloses an insoluble bone gelatin including about 10 percent growth factor. Insoluble bone gelatin is useful, for example, in preparing impaction bone grafts.

Abstract: The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes.

Abstract: A method of producing gelatin particles, including immersing a discharge spout in a hydrophobic solvent, discharging an aqueous gelatin solution from a nozzle tip into the hydrophobic solvent, and lifting, after discharging, the nozzle from the hydrophobic solvent, which can produce particles having an object particle size in a high yield, and can produce gelatin particles that do not essentially require a classification operation.

Abstract: A process for the preparation of gelatin solutions which is less than a physiologically relevant temperature, which is preferably less than about 37° C., the process comprising adding one or more transition point reducing agents, such as hydrogen bond breakers, reducing agents, plasticizers, surfactants, metal ions or denaturants (denaturing agents), to the gelatin solution. The reduced temperature processing can reduce damage to thermo sensitive pharmaceuticals ingredients or vitamins, or other heat sensitive ingredients.

Abstract: The invention provides an article of manufacture comprising a substantially non-immunogenic injectable collagen for implantation into humans. The invention further provides methods for preparing injectable collagen material by removing collagen-containing material from a non-human animal; washing in saline and alcohol; subjecting material to cellular disruption treatment; and digesting the material with a proteoglycan-depleting factor and/or glycosidase and optionally following with a capping treatment. The invention also provides an article of manufacture produced by the method. The injectable collagen material of the invention are substantially non-immunogenic and have substantially the same mechanical properties as a corresponding native soft tissue.

Abstract: An object of the present invention is to provide an anti-adhesion membrane that has no toxicity to a living body, has flexibility allowing itself to fit an affected part as a hydrated gel, is uniformly crosslinked, and is immediately absorbed in a living body after maintaining its shape in the living body for a certain period of time. The present invention provides anti-adhesion material, which comprises a thermally crosslinked gelatin film, and has a water content of 60 to 85% calculated by the following formula (1): water content (%)=[(Ws?Wd)/Ws]×100(%)??(1), in the formula (1), Ws representing a weight (wet weight) of the anti-adhesion material immersed in a phosphate buffered saline solution at a temperature of 25° C. for one hour, and Wd representing a weight (dry weight) of the anti-adhesion material dried completely using a vacuum drying apparatus.

Abstract: A method for purifying a membrane protein is disclosed which includes providing a test sample potentially including a target membrane protein; adding incremental amounts of a precipitating agent to the test sample to form one or more mixtures; and treating the one or more mixtures under conditions effective to obtain precipitated, purified target membrane protein if present in the test sample.

Abstract: This invention discloses two new VEGI isoforms named VEGI-192a and VEGI-192b consisting of 192 amino acid residues. These isoforms show endothelial cell-specific expression and share a C-terminal 151-residues segment with the previously described VEGI-174 and VEGI-251. Methods of using these isoforms of VEGI in diagnosing, screening agonist and antagonist of the isoforms, and treating various angiogenesis-related diseases are also disclosed.

Abstract: The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasonodium falciparum, at the erythrocyte stage, a process for purifying said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained therefrom. SE36 can be produced in Escherichia coli on a large scale by deleting all or part of polymerized serines of the 47 kd serine-repeat region, whereby high purification is permitted. The human IgG3 antibodies specifically binding to SE36 prevents highly effectively growth of the protozoa in the red blood cells to inhibit fever and cerebral malaria, and further prevent the death.

Abstract: A process for extracting gelatin from a marine invertebrate, comprising the steps of: 1) pre-treating a collagen-containing portion of the marine invertebrate with an alkali; and 2) extracting gelatin from the pre-treated collagen-containing portion with a weak acid solution at a temperature sufficient for conversion of collagen to gelatin to be effected.

Abstract: A method of manufacturing gelatin with reduced endotoxin content. The method comprises processing a starting material gelatin-containing solution containing gelatin and an endotoxin with an ultrafiltration film having a molecular weight cut-off falling within a range of from 20,000 to 300,000 and having a molecular weight cut-off capable of passing at least a portion of the gelatin contained in the starting material gelatin-containing solution to obtain a permeate that is a gelatin-containing solution with a reduced endotoxin content. A gelatin having an average molecular weight falling within a range of 1,000 to 300,000 and an endotoxin content of less than 1 EU/mL per 1.0 percent of protein.

Abstract: A process for the purification of recombinant human Chorionic Gonadotropin (hCG) from a sample of crude recombinant hCG in the supernatant of CHO cells comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography is performed twice and the final use of a size exclusion chromatography allows the purification from any residual traces of contaminants. The specific bioactivity of the highly purified hCG obtained form the process is particularly high, amounting to about 25,000 IU/mg.

Abstract: A process for producing non-woven silk fiber fabrics comprises the following steps: a) obtaining silk fibroin, for example either from silk cocoons, or silk textiles or waste silk; b) removing the sericin layer covering the silk fibroin fibers, when present; c) breaking the disulfide bonds between heavy (350 kDa) and light (27 kDa) chains of silk fibroin in order to obtain the production of chain fragments which serve as a specific cellular recognition sites promoting the attachment and growth of cells, d) homogenising of the material resulting from step c).

Abstract: A highly magnetically aligned metallothionein (MT) containing manganese (Mn) and cadmium (Cd) has been synthesized. The metallotionein has a formula of Mnx Cd7?x MT with x being in the range of 1 to 6. Its size and biological functions are similar as those of the native metallothionein as tested by dynamic light scattering, UV, and CD spectroscopic experimental methods. Its maximum magnetic moment per formula unit, in saturation field, is estimated to be 19.46 ?B, and persists from 277 to 330 K.

Abstract: A method of preparing a collagen sponge comprises mixing air into a collagen gel, so as to obtain a collagen foam which is dried. From the dried product thereby obtained, collagen sponge is obtained by isolating parts of sponge with a chamber diameter of more than 0.75 mm and less than 4 mm, or parts with an average chamber diagonal dimension of 3 mm. The collagen sponge may be used as a material for sealing wounds, possibly with a coating comprising a fibrin glue, such as a combination of fibrinogen, thrombin and aprotinin. A device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel is disclosed. An elongated collagen sponge having a through-going hole or bore and a flexible wall may be used for re-establishing walls in a mammalian gastrointestinal funnel or trachea system.

Abstract: A method of perlecan isolation (from the EHS tumor) which produces “clean” (i.e. substantially “pure”) perlecan is disclosed. Clean perlecan is thus produced in sufficient quantities for use in a number of different in vitro and in vivo assays. In addition, this isolation method exploits a newly discovered aggregating property of a ˜220 kDa heparan sulfate proteoglycan (HSPG) observed during gel filtration chromatography, which allows it to be effectively separated from non-aggregating perlecan. The method employs specific cation exchange, anion exchange, molecular sieve chromatography and immobilized GAG affinity chromatography. It is demonstrated that there are no other contaminating proteins in the perlecan and HSPG preparations, and that the perlecan core protein is intact. Improved, clean perlecan based, rodent models of fibrillar amyloid protein deposition, accumulation and/or persistence in tissues are disclosed.

Abstract: The invention provides an article of manufacture comprising a substantially non-immunogenic injectable collagen for implantation into humans. The invention further provides methods for preparing injectable collagen material by removing collagen-containing material from a non-human animal; washing in saline and alcohol; subjecting material to cellular disruption treatment; and digesting the material with a proteoglycan-depleting factor and/or glycosidase and optionally following with a capping treatment. The invention also provides an article of manufacture produced by the method. The injectable collagen material of the invention are substantially non-immunogenic and have substantially the same mechanical properties as a corresponding native soft tissue.

Abstract: The present invention relates to a method of applying mass spectrometry to analyzing peptides or proteins, especially in the proteome setting. More particularly, the invention relates to a mass spectrometry-based method for detection of protein/peptide phosphorylation wherein the side chains of glutamic acid and/or aspartic acid residues of said peptides or proteins are chemically modified as to improve the selectivity/efficiency of identification of the phosphorylated protein/peptide.

Abstract: A method of extracting and fractionating collagen-rich proteinaceous materials and derivatives from poultry skin tissue and the development of the proteinaceous materials to collagen-based protein ingredients that can function as meat replacer, texturizer, binder/filler, stabilizer, or protective colloids in processed meat products. The insoluble and soluble collagen products, collagen-based protein ingredients, water-dispersible collagen-based protein ingredients are produced by heating, separating, and rapidly cooling the solid-phase below its melting temperature to exploit reformation of the helical forms which produces a high concentration of coils, a phenomenon that accounts for its ability to form cold-set thermal reversible gels and gel strength.

Abstract: The present invention relates to a process for the recombinant production of a desired heterologous polypeptide with a clearly defined homogenous N-terminus in a bacteria host cell. A fusion comprising a peptide with the autoproteolytic activity of an autoprotease Npro of a pestivirus and the heterologous polypeptide is initially expressed in the form of cytoplasmic inclusion bodies in the host cell, the inclusion bodies are isolated and subsequently treated so that the desired heterologous polypeptide is cleaved autoproteolytically by the Npro activity of the fusion protein.